NCT04067336 2025-11-10First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid LeukemiaKura Oncology, Inc.Phase 1/2 Recruiting263 enrolled 1 FDA
NCT02000427 2024-05-28Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic LeukemiaAmgenPhase 2 Completed45 enrolled 24 charts 1 FDA
NCT02013167 2024-03-05Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)AmgenPhase 3 Terminated405 enrolled 27 charts 1 FDA
NCT04145531 2023-11-18An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)Jazz PharmaceuticalsPhase 2/3 Completed229 enrolled 17 charts 2 FDA